Trials / Completed
CompletedNCT02444637
Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD
Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage Alzheimer's Disease Having Coexisting Small Vessel Cerebrovascular Disease
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- National Neuroscience Institute · Academic / Other
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Rivastigmine, an acetylcholinesterase inhibitor which has been approved by FDA \& HSA, is authorized for use in the treatment of mild to moderate dementia of the Alzheimer's type. In this trial, the investigators will be studying the effectiveness of Rivastigmine in subjects with AD and cerebrovascular disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivastigmine |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2019-03-01
- Completion
- 2019-03-01
- First posted
- 2015-05-14
- Last updated
- 2021-03-05
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT02444637. Inclusion in this directory is not an endorsement.